MAI Wealth Advisors »

Halozyme Therapeutics shares owned by MAI Wealth Advisors

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by MAI Wealth Advisors from 13F filings

Historical chart of MAI Wealth Advisors investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by MAI Wealth Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by MAI Wealth Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $17k 15k 1.16
2025-06-30 $15k 15k 1.00
2025-03-31 $20k 19k 1.05
2024-12-31 $18k 19k 0.95

More positions owned by MAI Wealth Advisors

Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Apple Call Call Option (Principal) (AAPL)
Microsoft Corp Call Call Option (Principal) (MSFT)
Ishares Tr Core S&p Mcp Etf (IJH)
Nvidia Corporation Call Call Option (Principal) (NVDA)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Ishares Tr Core S&p Scp Etf (IJR)
Amazon Call Call Option (Principal) (AMZN)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Vanguard Specialized Funds Div App Etf (VIG)
Ishares Tr S&p 500 Val Etf (IVE)
Broadcom Call Call Option (Principal) (AVGO)
Alphabet Call Call Option (Principal) (GOOGL)
Ishares Tr Core Msci Eafe (IEFA)

View all positions for MAI Wealth Advisors

Top funds holding Halozyme Therapeutics

Steelhead Partners
Opti Capital Management
Linden Advisors
Millennium Management
MacKay Shields
DeepCurrents Investment Group
Tenor Capital Management
BlackRock
Lazard Asset Management
M&G
Calamos Advisors
Wellesley Investment Advisors
UBS O'Connor
Jpmorgan Chase & Co
State Street Corporation

View all funds holding Halozyme Therapeutics